First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers

  1. Felip, E.
  2. Moreno, V.
  3. Morgensztern, D.
  4. Curigliano, G.
  5. Rutkowski, P.
  6. Trigo, J.M.
  7. Calvo, A.
  8. Kowalski, D.
  9. Cortinovis, D.
  10. Plummer, R.
  11. Maio, M.
  12. Ascierto, P.A.
  13. Vladimirov, V.I.
  14. Cervantes, A.
  15. Zudaire, E.
  16. Hazra, A.
  17. T’jollyn, H.
  18. Bandyopadhyay, N.
  19. Greger, J.G.
  20. Attiyeh, E.
  21. Xie, H.
  22. Calvo, E.
Revue:
Cancer Chemotherapy and Pharmacology

ISSN: 1432-0843,  0344-5704

Année de publication: 2022

Volumen: 89

Número: 4

Pages: 499-514

Type: Article

DOI: 10.1007/S00280-022-04414-6 GOOGLE SCHOLAR lock_openAccès ouvert editor
La source de données: Scopus